ALEXANDRIA, Va. – An analysis of 1,800 lung cancer screening sites nationwide found that only 1.9% of more than 7 million current and former heavy smokers were screened for lung cancer in 2016, despite United States Preventive Services Task Force (USPSTF) and ASCO screening recommendations. This study, the first assessment of lung cancer screening rates since those recommendations were issued in 2013, will be presented at the upcoming 2018 ASCO Annual Meeting in Chicago.
Alexandria, Va. – An analysis published today in the American Society of Clinical Oncology’s (ASCO) Journal of Oncology Practice (JOP), suggests that including cancer drug costs in bundled payments under Medicare risks destabilizing the cancer care delivery environment. According to the report, Medicare reimbursement would vary widely in such a model depending on the mix of patient conditions practices treat, rather than the quality of care they provide—with reimbursement to practices that see a large volume of complex patients declining significantly from current levels.
ALEXANDRIA, Va. – Kevin Fitzpatrick will step down from his role as Chief Executive Officer of CancerLinQ LLC, a wholly owned non-profit subsidiarity of the American Society of Clinical Oncology (ASCO), on April 13 to pursue a new opportunity outside of ASCO. Richard L. Schilsky, MD, Chief Medical Officer (CMO) of ASCO, will serve as interim CEO. CancerLinQ LLC will initiate a global search for a permanent CEO to oversee the continued expansion and implementation of CancerLinQ®, ASCO’s big data platform designed to improve the quality of care for people with cancer.
Linda D. Bosserman, MD, FACP, FASCO, has been named Editor-in-Chief of the Journal of Oncology Practice (JOP), a publication of the American Society of Clinical Oncology (ASCO). Dr. Bosserman is a recognized leader in cancer care delivery with a deep understanding of the issues impacting all types of oncology practices.
ASCO Statement on JAMA Internal Medicine’s Cigarette, Cigar, and Pipe Use Mortality Risk Study
Statement from Bruce E. Johnson, MD, FASCO, President of the American Society of Clinical Oncology (ASCO)
ALEXANDRIA, Va. – A pilot study of cancer survivors ages 11-15 suggests that a web-based, interactive intervention that provides rewards for exercising can motivate kids to stay physically active. Moderate to vigorous physical activity increased by an average of nearly 5 minutes a week in the group that used the intervention and decreased by an average of over 24 minutes in the control group. These findings will be presented at the upcoming 2018 Cancer Survivorship Symposium in Orlando, Florida.
ALEXANDRIA, Va. – Cancer care guidelines recommend that cancer survivors who experience sexual dysfunction after cancer treatment use therapeutic aids to help improve their sexual health. However, a new study of 25 leading cancer centers found that 87% of the centers reported having no sexual aids available on site for men, and 72% reported having no aids for women. These findings will be presented at the upcoming 2018 Cancer Survivorship Symposium in Orlando, Florida.
A new study suggests that a large percentage of adolescents and young adults (AYAs) who have been treated for cancer do not seek follow-up care after their primary treatment ends, despite its importance for long-term health. AYA cancer survivors are at increased risk for heart problems, infertility, and secondary cancers from cancer treatment.
New findings from a clinical trial of women with breast cancer suggest that guided exercise with a physical therapist after lymph node dissection helps women regain their range of arm motion more quickly. These findings will be presented at the upcoming 2018 Cancer Survivorship Symposium in Orlando, Florida.
The American Society of Clinical Oncology (ASCO) today released its review of leading oncology pathway vendors in the United States. "Oncology Clinical Pathways: Charting the Landscape of Pathway Providers," published in the Journal of Oncology Practice (JOP), examines the clinical pathways offered by six commercial vendors using the society's criteria for high-quality clinical pathways.
In a phase III clinical trial of people with previously untreated metastatic renal cell cancer (mRCC), combining immunotherapy atezolizumab with targeted therapy bevacizumab delayed cancer growth by about three months longer than sunitinib, another targeted therapy.
"Over the past few decades we’ve seen global cancer death rates drop thanks to dramatic improvements in diagnosis and treatment. But the unfortunate reality is that millions of patients worldwide are not yet reaping the benefits of the progress we’ve made because of inability to access care. All too often, where someone lives dictates their chances of surviving cancer."
CancerLinQ LLC and the American College of Medical Genetics and Genomics (ACMG), the medical specialty society for clinical and laboratory genetics professionals, have entered into a programmatic collaboration. CancerLinQ®, the American Society of Clinical Oncology’s (ASCO) health information technology platform designed by oncologists for oncologists to leverage the power of big data to help improve the quality of care for patients with cancer, will benefit from the knowledge and expertise of ACMG leadership and members.
SAN FRANCISCO – Eight noteworthy studies exploring the implications of immuno-oncology for patient care will be presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. The meeting will take place January 25-27 at the San Francisco Marriott Marquis in San Francisco, California. These notable abstracts discuss the efficacy of immunotherapy in rare cancers, biomarkers to predict which patients will benefit most, and managing the adverse effects of immune-based treatments.
We are deeply concerned about the sequestration cuts that would be triggered by passage of the Tax Cuts and Jobs Act. The core mission of the American Society of Clinical Oncology (ASCO) is to ensure that cancer patients have meaningful access to high-quality cancer care. We fear that the current proposal will harm patients with cancer by reducing access to care, a situation that could adversely impact treatment needed to extend and save patients' lives.